BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
calcium channel activity
,
Inflammatory disorder
,
Intestine
,
DNA fingerprint
,
TGFB1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
DI 1
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Livers of mice treated with PPARalpha pathway inhibitors
Assessment of ex vivo prostaglandin pathway activation in hematopoietic stem cells
Explore Curated Studies Results
Literature
Most Relevant Literature
DNA selection by the master transcription factor PU.1.
Transcriptional regulation of the HIV-1 inhibitory factor human mannose receptor 1 by the myeloid-sp…
Effect of Salmonella pathogenicity island 1 and 2 (SPI-1 and SPI-2) deletion on intestinal colonizat…
Epigallocatechin gallate regulates the myeloid-specific transcription factor PU.1 in macrophages.
PU.1 negatively regulates tumorigenesis in non-small-cell lung cancer.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Pharmacokinetics of C6 Ketone Di-ester
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients…
Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants …
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ